DIVISLAB's weekly performance was disappointing, with a -1.6% return, outperforming only DRREDDY among its peers. The stock's volatility was moderate at 25.45%, lower than SUNPHARMA but higher than CIPLA and DRREDDY. The Sharpe Ratio of -0.24 indicates a poor risk-adjusted return, and the Max Drawdown of -2.77% suggests a relatively high level of risk. Overall, DIVISLAB's performance was lackluster, with a moderate level of volatility.

[Volatility: 25.45%]